

#9
7.7.7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Gras-Masse, et al.	Examiner:	Shanon A. Foley
Serial No.:	09/555,780	Group Art Unit:	1648
Filed:	June 2, 2000	Docket:	1091-2 PCT/US
For:	MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE AND THEIR THERAPEUTIC USES	Dated:	March 7, 2001

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

20231 on March 7, 2001

Dated: 3/7/01

Julie L. Watts

RESPONSE TO RESTRICTION REQUIREMENT

Sir:


This communication is in response to the Restriction Requirement mailed February 8, 2001. In the Restriction Requirement, it is stated that Applicants are required to select one species from the antigenic determinants and one species of the lipoproteins to be examined.

Accordingly, for the antigenic determinant species, Applicants elect c) CTL antigenic determinant from HIV, Claims 10, 14, 21, and 24. With regard to the lipoproteins, Applicants elect species b) GAG 253, Claim 11.

The Restriction Requirement also indicates that the specification is objected to for failure to append SEQ ID Nos. to the specific sequences in the specification and the claims. Applicants note that a Supplemental Preliminary Amendment was filed on January 2, 2001 in order to amend the specification and claims to reflect the sequences contained in the sequence listing and to include appropriate headings in accordance with U.S. practice.

Accordingly, this application is now believed to be in condition for examination on the merits.

Respectfully submitted,


James F. Harrington
Registration No.: 44,741
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
JFH:jlw